Etesevimab is a humanized anti-SARS-CoV-2 neutralizing monoclonal antibody, co-developed by Eli Lilly and Company and Junshi Biosciences. It binds to the spike protein of SARS-CoV-2, blocking viral attachment and entry into host cells. It is authorized for use in combination…
Cejemly® is the commercial brand name of Sugemalimab Injection, a fully human anti-programmed death ligand 1 (anti-PD-L1) monoclonal antibody developed by CStone Pharmaceuticals and Pfizer. It binds to PD-L1 expressed on tumor cells and immune cells, blocking its interaction with…
Hansizhuang® is the commercial brand name of Serplulimab Injection, a recombinant humanized anti-programmed death 1 (anti-PD-1) monoclonal antibody developed by Henlius Biotech. It binds to the PD-1 receptor on T cells, blocking its interaction with PD-L1/PD-L2, thereby restoring the immune…
CARVYKTI® is the commercial brand name of ciltacabtagene autoleucel, a BCMA-directed genetically modified autologous T-cell immunotherapy developed by Janssen Biotech. It involves engineering the patient’s own T cells to express a chimeric antigen receptor (CAR) targeting B-cell maturation antigen (BCMA),…
Ensacove® is the commercial brand name of Ensartinib Hydrochloride Capsules, an orally active second-generation anaplastic lymphoma kinase (ALK) inhibitor developed by Betta Pharmaceuticals. It selectively inhibits ALK tyrosine kinase activity, blocking downstream signaling pathways to suppress the proliferation and survival…
SOLIRIS® is the commercial brand name of Eculizumab Injection, a humanized anti-C5 monoclonal antibody developed by Alexion Pharmaceuticals. It binds to complement protein C5, preventing its cleavage into C5a and C5b-9, thereby inhibiting terminal complement-mediated hemolysis and inflammation. Main IndicationsTreatment…
TEGLUTIK® is the commercial brand name of Riluzole Oral Suspension, an orally active antiglutamatergic agent. It inhibits glutamate release and blocks voltage-dependent sodium channels, exerting neuroprotective effects in amyotrophic lateral sclerosis (ALS). Main IndicationsTreatment of amyotrophic lateral sclerosis (ALS) in…
Taltz® is the commercial brand name of Ixekizumab Injection, a humanized anti-IL-17A monoclonal antibody developed by Eli Lilly. It selectively binds to interleukin 17A (IL-17A), inhibiting its interaction with the IL-17 receptor and blocking the inflammatory cascade in autoimmune diseases.…
Kisqali® is the commercial brand name of Ribociclib Tablets, an orally active CDK4/6 inhibitor developed by Novartis. It selectively inhibits cyclin-dependent kinases 4 and 6 (CDK4/6), blocking the phosphorylation of retinoblastoma (Rb) protein to arrest the cell cycle in G1…
Amaryl® is the commercial brand name of Glimepiride Tablets, an orally active sulfonylurea antidiabetic agent developed by Sanofi. It stimulates pancreatic beta cells to secrete more insulin, thereby lowering blood glucose levels. Main IndicationsTreatment of type 2 diabetes mellitus in…